This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Entrada Therapeutics, Inc., 5Am Venture Management, LLC. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: Jason Ruth: Innovator in Mitochondrial Research
Introduction
Jason Ruth is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of mitochondrial research, particularly in the treatment of mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). With a total of 3 patents, his work is paving the way for innovative therapeutic approaches.
Latest Patents
Ruth's latest patents focus on compositions and methods for treating MNGIE. These patents disclose compounds that possess cell-penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds include at least one cell-penetrating peptide (CPP) moiety and a thymidine phosphorylase or an active fragment or analog thereof. The CPP is coupled, either directly or indirectly, to the TP, enhancing the efficacy of the treatment.
Career Highlights
Jason Ruth is currently associated with Entrada Therapeutics, Inc., where he continues to advance his research and development efforts. His innovative work in the field has garnered attention and respect from peers and industry professionals alike.
Collaborations
Ruth collaborates with notable colleagues, including Natarajan Sethuraman and Dehua Pei. Their combined expertise contributes to the advancement of research in mitochondrial diseases.
Conclusion
Jason Ruth is a key figure in the field of mitochondrial research, with a focus on developing effective treatments for MNGIE. His innovative patents and collaborations highlight his commitment to improving patient outcomes through scientific advancements.